This is an old revision of this page, as edited by BD2412(talk | contribs) at 03:09, 6 June 2024(→top: Clean up spacing errors around ref tags., replaced: . <ref → .<ref). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 03:09, 6 June 2024 by BD2412(talk | contribs)(→top: Clean up spacing errors around ref tags., replaced: . <ref → .<ref)
Its mechanism of action and clinical effects closely resemble those of nifedipine and the other dihydropyridine calcium channel blockers (amlodipine, felodipine), except that nicardipine is more selective for cerebral and coronary blood vessels. It is primarily a peripheral arterial vasodilator, thus unlike the nitrovasodilators (nitroglycerin and nitroprusside), cardiac preload is minimally affected. It has the longest duration among parenteral CCBs.[2][3] As its use may lead to reflex tachycardia, it is advisable to use it in conjunction with a beta-blocker.[3][2]
It was patented in 1973 and approved for medical use in 1981.[4]
Nicardipine was approved by the FDA in December 1988. The patent for both Cardene and Cardene SR expired in October 1995.[5]
^Huang RI, Patel P, Walinsky P, Fischman DL, Ogilby JD, Awar M, et al. (November 2006). "Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention". Catheterization and Cardiovascular Interventions. 68 (5): 671–676. doi:10.1002/ccd.20885. PMID17034064. S2CID37071966.
^ abFreeman BS (2014). "Vasodilators". In Freeman BS, Berger JS (eds.). Anesthesiology Core Review: Part One Basic Exam. McGraw Hill. ISBN978-0-07-182137-7.